FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886287284> ?p ?o ?g. }

• W2886287284 abstract "Background and Objectives Multiple myeloma (MM) is a B-cell malignancy involving excessive proliferation and accumulation of atypical plasma cells specifically in the bone marrow (BM) niche. Multiple primary and secondary genetic alterations play crucial role in deregulating the biology of myeloma cells giving them a malignant phenotype, hence generating a need for novel efficacious and safe therapeutic agents. Increased expression of telomerase and higher telomerase activity (RTA) has been found in majority of cancer but displays very low activity in majority of normal somatic cells. Therefore, this maiden attempt unveils the therapeutic potential of Di-indolylmethane alone or in combination with dexamethasone by targeting telomerase activity in myeloma cells. Methodology In this study, two myeloma cell lines (RPMI8226 & U266) were procured from ATCC (Manassas, VA). Di-indolylmethane (DIM) and dexamethasone (Dexa) were purchased from Sigma Aldrich (St. Louis, MO). In in-vitro study, IC50 concentration of DIM and Dexa on both cells was determined using MTT dye. Cell-cycle and apoptosis assay was performed to determine the anti-proliferative and apoptotic effects of DIM and Dexa alone or in combination. Further, caspase-3/7 activity and mitochondrial membrane potential (MMP) was determined to assessed pathway of apoptosis. Effects of single drug or combination on telomerase activity were also assessed in both myeloma cells. Results Results demonstrated that, DIM showed an IC50 conc. of 40μM in both myeloma cells while these cells were resistant to Dexa even at higher dose. In cell cycle assay, significant increase in sub-G0/G1 phase were observed with increasing dose of DIM while combination of DIM and Dexa significantly increased sub-G0/G1 cell populations in comparison to vehicle control. Similarly annexin-V/PI apoptosis assay also demonstrated increased apoptosis of both myeloma cells. Further, DIM alone or in combination with Dexa demonstrated drastic increased caspase-3/7 activity and significant decrease in MMP in both myeloma cells. Additionally, increasing dose of DIM significantly decreased telomerase activity and combination of DIM and Dexa was much more potent in decreasing telomerase activity in comparison to vehicle treatment and DIM alone. Conclusions In nutshell, this maiden attempt provided initial evidences of therapeutic potential of DIM as novel anticancer agent alone or in combination with standard chemotherapeutic agent Dexa. Further, novel combination of DIM and Dexa was much more potential in inducing apoptosis cell death and chemo-sensitizing myeloma cells than single drug treatment regime. Also intrinsic pathway of apoptosis was followed by DIM in inducing apoptosis in myeloma. Furthermore, decreased TA by DIM emphasized its potential as novel molecular therapeutic target which need further validation. Citation Format: Raman Kumar, Nidhi Gupta, . Himani, Alpana Sharma. Novel combination of Di-indolylmethane (DIM) and dexamethasone induces apoptosis in myeloma cells by modulating the telomerase activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4392." @default.
• W2886287284 created "2018-08-22" @default.
• W2886287284 creator A5053783690 @default.
• W2886287284 creator A5071169692 @default.
• W2886287284 creator A5078710789 @default.
• W2886287284 creator A5083339090 @default.
• W2886287284 date "2018-07-01" @default.
• W2886287284 modified "2023-09-25" @default.
• W2886287284 title "Abstract 4392: Novel combination of Di-indolylmethane (DIM) and dexamethasone induces apoptosis in myeloma cells by modulating the telomerase activity" @default.
• W2886287284 doi "https://doi.org/10.1158/1538-7445.am2018-4392" @default.
• W2886287284 hasPublicationYear "2018" @default.
• W2886287284 type Work @default.
• W2886287284 sameAs 2886287284 @default.
• W2886287284 citedByCount "0" @default.
• W2886287284 crossrefType "proceedings-article" @default.
• W2886287284 hasAuthorship W2886287284A5053783690 @default.
• W2886287284 hasAuthorship W2886287284A5071169692 @default.
• W2886287284 hasAuthorship W2886287284A5078710789 @default.
• W2886287284 hasAuthorship W2886287284A5083339090 @default.
• W2886287284 hasConcept C104317684 @default.
• W2886287284 hasConcept C134018914 @default.
• W2886287284 hasConcept C153911025 @default.
• W2886287284 hasConcept C185592680 @default.
• W2886287284 hasConcept C190283241 @default.
• W2886287284 hasConcept C203014093 @default.
• W2886287284 hasConcept C2776364478 @default.
• W2886287284 hasConcept C2780401358 @default.
• W2886287284 hasConcept C2780783641 @default.
• W2886287284 hasConcept C29537977 @default.
• W2886287284 hasConcept C502942594 @default.
• W2886287284 hasConcept C54355233 @default.
• W2886287284 hasConcept C55493867 @default.
• W2886287284 hasConcept C62112901 @default.
• W2886287284 hasConcept C81885089 @default.
• W2886287284 hasConcept C86803240 @default.
• W2886287284 hasConcept C94581717 @default.
• W2886287284 hasConceptScore W2886287284C104317684 @default.
• W2886287284 hasConceptScore W2886287284C134018914 @default.
• W2886287284 hasConceptScore W2886287284C153911025 @default.
• W2886287284 hasConceptScore W2886287284C185592680 @default.
• W2886287284 hasConceptScore W2886287284C190283241 @default.
• W2886287284 hasConceptScore W2886287284C203014093 @default.
• W2886287284 hasConceptScore W2886287284C2776364478 @default.
• W2886287284 hasConceptScore W2886287284C2780401358 @default.
• W2886287284 hasConceptScore W2886287284C2780783641 @default.
• W2886287284 hasConceptScore W2886287284C29537977 @default.
• W2886287284 hasConceptScore W2886287284C502942594 @default.
• W2886287284 hasConceptScore W2886287284C54355233 @default.
• W2886287284 hasConceptScore W2886287284C55493867 @default.
• W2886287284 hasConceptScore W2886287284C62112901 @default.
• W2886287284 hasConceptScore W2886287284C81885089 @default.
• W2886287284 hasConceptScore W2886287284C86803240 @default.
• W2886287284 hasConceptScore W2886287284C94581717 @default.
• W2886287284 hasLocation W28862872841 @default.
• W2886287284 hasOpenAccess W2886287284 @default.
• W2886287284 hasPrimaryLocation W28862872841 @default.
• W2886287284 hasRelatedWork W1420964188 @default.
• W2886287284 hasRelatedWork W2351588254 @default.
• W2886287284 hasRelatedWork W2354128257 @default.
• W2886287284 hasRelatedWork W2355537558 @default.
• W2886287284 hasRelatedWork W2363589313 @default.
• W2886287284 hasRelatedWork W2376933360 @default.
• W2886287284 hasRelatedWork W2378222954 @default.
• W2886287284 hasRelatedWork W2379033026 @default.
• W2886287284 hasRelatedWork W3025536567 @default.
• W2886287284 hasRelatedWork W3030640751 @default.
• W2886287284 isParatext "false" @default.
• W2886287284 isRetracted "false" @default.
• W2886287284 magId "2886287284" @default.
• W2886287284 workType "article" @default.